Congress Asset Management Co. Has $20.91 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH

Congress Asset Management Co. increased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 14.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 339,018 shares of the company’s stock after acquiring an additional 43,595 shares during the period. Congress Asset Management Co. owned about 0.71% of Prestige Consumer Healthcare worth $20,914,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PBH. Dimensional Fund Advisors LP increased its position in shares of Prestige Consumer Healthcare by 4.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after purchasing an additional 119,459 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the last quarter. Westwood Holdings Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 2.4% in the 2nd quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company’s stock valued at $70,420,000 after buying an additional 20,626 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after buying an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in shares of Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after buying an additional 86,373 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Jefferies Financial Group dropped their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $76.50.

Prestige Consumer Healthcare Stock Performance

PBH opened at $62.09 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare Inc. has a 12-month low of $57.25 and a 12-month high of $89.37. The business has a 50 day moving average of $65.72 and a 200-day moving average of $63.22. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of 16.42, a PEG ratio of 1.97 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period in the previous year, the firm posted $1.22 earnings per share. The firm’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).